Key result
Pharmacist-led care linked to a ~118% higher rate of antihypertensive treatment intensification vs usual care.
Why the study?
Therapeutic inertia challenges optimal blood pressure control, prolonging high blood pressure exposure and cardiovascular risk among older patients in low- and middle-income countries.
Does pharmacist-led care reduce the time to antihypertensive treatment intensification in older patients with uncontrolled hypertension?
Cohort (n=422)
Yes
Does pharmacist-led care reduce the time to antihypertensive treatment intensification in older patients with uncontrolled hypertension?
Pharmacist-led interventions significantly accelerate antihypertensive treatment intensification and improve blood pressure control in older patients with uncontrolled hypertension.
Answers are grounded in this paper and cite their sources.
Supports faster intensification with pharmacist-led care in older hypertension; leaves open outcome benefits pending randomized trials.
Background: Therapeutic inertia is a significant challenge to optimal blood pressure control, resulting in prolonged exposure to high blood pressure and increased cardiovascular risk, especially among older patients in low- and middle-income countries. Objectives: The current study assessed the impact of interventions by pharmacists on the time to antihypertensive treatment intensification among older patients with uncontrolled hypertension in Northwest Ethiopia. Design: A multicenter prospective cohort study was conducted from January to July 2025 in three tertiary hospitals in Northwest Ethiopia. Methods: A total of 422 older hypertensive patients with uncontrolled blood pressure were enrolled and followed up either in the pharmacist-led care or usual care. The interventions by pharmacists included recommendations for treatment intensification, medication review, adherence, and resolution of drug-related problems. The primary outcome was time to antihypertensive treatment intensification. Kaplan–Meier survival analysis and Cox proportional hazards regression were employed to evaluate the time-to-event outcomes and factors. Results: Patients receiving pharmacist-led care experienced significantly faster treatment intensification than those receiving usual care, with a median time of 28 days versus 63 days. A higher proportion of patients in the pharmacist-led group achieved treatment intensification within 30, 60, and 90 days. Faster treatment intensification (adjusted hazard ratio (AHR) 2.18) was independently linked to pharmacist-led care. The intervention group showed greater systolic and diastolic blood pressure reductions, as well as a higher percentage of patients who achieved blood pressure control at follow-up. In addition, higher baseline systolic blood pressure was linked to faster intensification of treatment. Conclusion: Pharmacist-led interventions significantly reduced therapeutic inertia by accelerating antihypertensive treatment intensification and improving blood pressure control. Integrating pharmacists into multidisciplinary hypertension care may represent an effective and scalable strategy to improve hypertension outcomes in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Dagnew et al. (2026) conducted a cohort in Uncontrolled hypertension (n=422). Pharmacist-led care vs. Usual care was evaluated on Time to antihypertensive treatment intensification (AHR 2.18). Pharmacist-led care accelerated antihypertensive treatment intensification compared to usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: